JIANGXI BIOLOGY(06915.HK): Veterinary Tetanus Antitoxin Production Line Officially Put into Operation
NewTimeSpace News: On 27 July 2026, JIANGXI BIOLOGY(06915.HK) issued an announcement stating that the production line for veterinary tetanus antitoxin (veterinary TAT) under its wholly-owned subsidiary Chifeng Boen Pharmaceutical Co., Ltd. officially went into production in Chifeng City, Inner Mongolia Autonomous Region on 20 July 2026.
The announcement notes that this product is mainly applied to prevent and treat animal tetanus caused by trauma or surgery. It provides passive immune protection for animals by neutralizing tetanus toxins.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- JIANGXI BIOLOGY(06915.HK): Stabilisation Period Concludes, Over-Allotment Option Lapses
- Jiangxi Biotech (06915.HK)Slumps 14.29% on Listing Day, Quoted at HK$9.60
- JIANGXI BIOLOGY(06915.HK) Launches Public Offering Today, Entry Fee Approximately HK$6,595.86
- Jiangxi Biology Passes HKEX Hearing, World’s Largest Provider of Human Tetanus Antitoxin
- JIANGXI BIO(06915.HK) closed 24.49% higher on Jul 24, eading the gains in the Hang Seng Pharmaceuticals & Biotechnology Sector
